Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Feb 9;17(2):79-84.
doi: 10.1016/j.rpor.2012.01.006. eCollection 2012.

Results of combined radiotherapy and hormonal treatment of prostate cancer patients with initial PSA value >40 ng/ml

Jiri Kubeš  1 , Cvek Jakub  2 , Vondráček Vladimir  1 , Dvořák Jan  1 , Argalacsová Sona  1 , Navrátil Matej  1 , Buřil Jan  1
Affiliations

Results of combined radiotherapy and hormonal treatment of prostate cancer patients with initial PSA value >40 ng/ml

Jiri Kubeš et al. Rep Pract Oncol Radiother. .

Abstract

Aim: To evaluate the outcome of prostate cancer patients with initial PSA value >40 ng/ml.

Background: The outcome of prostate cancer patients with very high initial PSA value is not known and patients are frequently treated with palliative intent. We analyzed the outcome of radical combined hormonal treatment and radiotherapy in prostate cancer patients with initial PSA value >40 ng/ml.

Methods: Between January 2003 and December 2007 we treated, with curative intent, 56 patients with non-metastatic prostate cancer and initial PSA value >40 ng/ml. The treatment consisted of two months of neoadjuvant hormonal treatment (LHRH analog), radical radiotherapy (68-78 Gy, conformal technique) and an optional two-year adjuvant hormonal treatment.

Results: The median time of follow up was 61 months. 5-Year overall survival was 90%. 5-Year biochemical disease free survival was 62%. T stage, Gleason score, PSA value, and radiotherapy dose did not significantly influence the outcome. Late genitourinal and gastrointestinal toxicity was acceptable.

Conclusion: Radical treatment in combination with hormonal treatment and radiotherapy can be recommended for this subgroup of prostate cancer patients with good performance status and life expectancy.

Keywords: High risk; PSA; Prostate cancer; Radiotherapy.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Overall survival (a) and biochemical-disease free survival (bDFS) (b).
See this image and copyright information in PMC

References

    1. Caire A.A., Sun L., Lack B.D. Predicting non-organ-confined prostate cancer in men diagnosed after 2000. Prostate Cancer Prostatic Dis. 2010;13:248–251. - PubMed
    1. Partin A.W., Kattan M.W., Subong E.N. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997;277:1445–1451. - PubMed
    1. Gallina A., Jeldres C., Chun F.K. Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL. Eur Urol. 2007;52:1374–1380. - PubMed
    1. Anim J.T., Kehinde E.O., Prasad A. Relationship between serum prostate specific antigen and the pattern of inflammation in both benign and malignant prostatic disease in Middle Eastern men International. Urol Nephrol. 2006;38:27–32. - PubMed
    1. Schirrmeister H., Guhlmann A., Elsner K. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med. 1999;40:1623–1629. - PubMed